Dextromethorphan and guaifenesin use must be monitored carefully in individuals with "poor metabolizer" CYP2D6 enzyme concentrations and sufferers who're sedated. This combination medication features a large median harmful dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these individuals. et al. The impact of CYP2D6 polymorphism and https://geoffroyscatforsale00987.wssblogs.com/30191199/5-easy-facts-about-dextromethorphan-dxm-for-sale-in-copyright-described